FDA backs second rare disease drug from Ultragenyx in the space of a fortnightThe FDA has approved a second rare disease drug from California-based Ultragenyx in the space of a fortnight, for treatment Share XFDA backs second rare disease drug from Ultragenyx in the space of a fortnighthttps://pharmaphorum.com/news/fda-backs-ultragenyxs-second-rare-disease-drug-in-the-space-of-a-fortnight/
Key payer backs Ultragenyx’ rare rickets drug at $200,000 per yearExpress Scripts’ Miller backs “responsible” price Share XKey payer backs Ultragenyx’ rare rickets drug at $200,000 per yearhttps://pharmaphorum.com/sales-marketing/key-payers-backs-ultragenyx-rare-rickets-drug-200000-per-year/